藥物發現服務的全球市場：市場規模和份額分析（按工藝、類型、藥物類型、治療領域和最終用戶）、行業需求預測（截至 2030 年）

市場概況

2023年全球藥物發現服務市場規模預估為210億美元，預計2030年將達542億美元。 2024 年至 2030 年複合年增長率為 14.7%。

生物製藥和製藥行業不斷增加的研發投入、對分析測試設施外包的需求不斷增長、研究罕見藥物和罕見疾病的步伐以及內部藥物開發的高成本正在為世界範圍內的問題打開大門為行業帶來新的收入。

關鍵見解

2023年，在藥物發現服務業中，Hit-to-Lead識別類別佔最大份額，達到35%。

到2023年，化學品類別將以60%的市佔率佔據首位。

小分子藥物類別在業界佔有很大份額，對於全球新療法的出現至關重要。 2020年，小分子藥物佔特種藥物銷售額的50%，佔FDA核准量的75%以上。

近年來，北美地區在藥物開發服務方面佔據了最大的行業份額，達到55%。

本報告分析了全球藥物發現服務市場，包括市場的基本結構、最新情況、主要促進和抑制因素以及全球、按地區和主要國家的市場規模前景（關於以貨幣為基礎，2017-2030 ），按工藝、類型、藥物類型、治療領域和最終用戶劃分的詳細趨勢、市場競爭的現狀以及主要公司的概況。

目錄

第1章研究範圍

第2章研究方法

第 3 章執行摘要

第 4 章市場指標

第5章產業展望

• 市場動態
  • 趨勢
  • 促進因素
  • 抑制因素/挑戰
  • 促進/抑制因子影響分析
• 新型冠狀病毒感染 (COVID-19) 的影響
• 波特五力分析

第6章世界市場

• 摘要
• 市場收入：依流程分類（2017-2030 年）
• 市場收入：依類型劃分（2017-2030 年）
• 市場收入：依藥物類型劃分（2017-2030 年）
• 市場收入：依治療領域劃分（2017-2030 年）
• 市場收入：以最終用戶劃分（2017-2030 年）
• 市場收入：按地區劃分（2017-2030 年）

第7章北美市場

• 摘要
• 市場收入：依流程分類（2017-2030 年）
• 市場收入：依類型劃分（2017-2030 年）
• 市場收入：依藥物類型劃分（2017-2030 年）
• 市場收入：依治療領域劃分（2017-2030 年）
• 市場收入：以最終用戶劃分（2017-2030 年）
• 市場收入：依國家/地區劃分（2017-2030 年）

第8章歐洲市場

第9章亞太市場

第10章拉丁美洲市場

第11章中東及非洲市場

第12章美國市場

• 摘要
• 市場收入：依流程分類（2017-2030 年）
• 市場收入：依類型劃分（2017-2030 年）
• 市場收入：依藥物類型劃分（2017-2030 年）
• 市場收入：依治療領域劃分（2017-2030 年）
• 市場收入：以最終用戶劃分（2017-2030 年）

第13章加拿大市場

第14章德國市場

第15章法國市場

第16章英國市場

第17章義大利市場

第18章西班牙市場

第19章日本市場

第20章中國市場

第21章印度市場

第22章澳洲市場

第23章韓國市場

第24章巴西市場

第25章墨西哥市場

第26章沙烏地阿拉伯市場

第27章南非市場

第 28 章阿聯酋 (UAE) 市場

第29章競爭態勢

• 市場參與者及其提供的產品/服務的列表
• 主要公司的競爭基準
• 各大公司的產品基準
• 近期策略發展狀況

第30章公司簡介

• Charles River Laboratories International Inc.
• Eurofins Scientific Limited
• Frontage Laboratories Inc.
• Galapagos NV
• General Electric
• Laboratory Corporation of America Holdings
• Thermo Fisher Scientific Inc.
• Syngene International Limited
• WuXi AppTec

第31章 附錄

Market Overview

In 2023, the estimated value of the global drug discovery services market is USD 21.0 billion, projected to reach USD 54.2 billion by 2030. This growth represents a Compound Annual Growth Rate of 14.7% during the period from 2024 to 2030.

The growing research and development investments of the biopharmaceutical and pharmaceutical industries, the increasing need for outsourcing analytical testing facilities, steps for orphan drug and rare illness research, and the costly nature of the in-house drug expansion procedure are all opening up new revenue gates in the worldwide industry.

One of the reasons for the escalating demand for outsourcing clinical testing and analytical research services for biopharmaceutical drugs is the rising expenditure of R&D activities that are majorly channelled toward orphan drugs that are meant to suppress rare conditions.

On the other hand, the biopharmaceutical industry has been growing exceptionally due to the ever-increasing demands for biologics and the invention of and manufacturing of several innovative and life-saving drugs. Moreover, the bioscience industry profits from the investment in research of the new covered drugs for common and rare diseases. The market of drug discovery is also solving the problem of patents' expiration as well as the growing need for biologics in emerging economies.

Key Insights

In 2023, the hit-to-lead identification category held the largest share of 35% in the drug discovery services industry.

This procedure is vital in initial drug research and includes outsourcing to attain economies of scale and effectiveness for medicinal businesses.

Pioneering in-silico methods such as computer-aided drug discovery and structure-based medication designs contribute to the development of this category.

High-throughput screening plays a major role in hit-to-lead identification, eased by improvements in robotics, liquid management, plate reader discovery, and computing power.

Because of the dedicated and expensive nature of HTS, several organizations, particularly those with limited backing, select to outsource such services to Contract Research Organizations for high-quality and lucrative solutions.

In 2023, the chemistry category grips a leading share of 60% in the market.

Besides drug discovery, medicinal chemistry provides action at every stage, starting from pre-clinical evaluation to the delivery of a drug candidate.

The medical chemistry market is growing as companies work to find new ways to outsource tasks such as R&D services.

Such growth is continuously fostered by an increase in the number of overhead costs incurred during the pharmaceutical discovery and development processes.

Small-molecule drugs category grips a substantial industry share and is vital in emerging novel treatments worldwide.

Small-molecule drugs account for 50% of specialty drug sales and comprised over 75% of all FDA approvals in 2020.

They play a critical role in treating cancer, autoimmune diseases, cardiovascular disorders, and respiratory conditions.

The North American region holds the largest industry share of 55% in the recent years in drug advancement services.

The region aids from several Contract Research Organizations and Contract Manufacturing Organizations backing key pharmaceutical and biopharmaceutical firms, contributing to industry growth.

Numerous newly developed drugs have their patents held in the U.S., additionally boosting the industry.

Reasons propelling industry development include an increasing elderly populace, growing occurrence of chronic illnesses, technical improvements in biotechnology and pharmaceutical industries, recognized reimbursement guidelines, advanced medicinal infrastructure, rising awareness of initial disease diagnosis, and the reequipment for better patient care.

Table of Contents

Chapter 1. Research Scope

• 1.1. Research Objectives
• 1.2. Market Definition
• 1.3. Analysis Period
• 1.4. Market Size Breakdown by Segments
  • 1.4.1. Market size breakdown, by process
  • 1.4.2. Market size breakdown, by type
  • 1.4.3. Market size breakdown, by drug type
  • 1.4.4. Market size breakdown, by therapeutic area
  • 1.4.5. Market size breakdown, by end user
  • 1.4.6. Market size breakdown, by region
  • 1.4.7. Market size breakdown, by country
• 1.5. Market Data Reporting Unit
  • 1.5.1. Value
• 1.6. Key Stakeholders

Chapter 2. Research Methodology

• 2.1. Secondary Research
  • 2.1.1. Paid
  • 2.1.2. Unpaid
  • 2.1.3. P&S Intelligence database
• 2.2. Primary Research
• 2.3. Market Size Estimation
• 2.4. Data Triangulation
• 2.5. Currency Conversion Rates
• 2.6. Assumptions for the Study
• 2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

• 5.1. Market Dynamics
  • 5.1.1. Trends
  • 5.1.2. Drivers
  • 5.1.3. Restraints/challenges
  • 5.1.4. Impact analysis of drivers/restraints
• 5.2. Impact of COVID-19
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Bargaining power of buyers
  • 5.3.2. Bargaining power of suppliers
  • 5.3.3. Threat of new entrants
  • 5.3.4. Intensity of rivalry
  • 5.3.5. Threat of substitutes

Chapter 6. Global Market

• 6.1. Overview
• 6.2. Market Revenue, by Process (2017-2030)
• 6.3. Market Revenue, by Type (2017-2030)
• 6.4. Market Revenue, by Drug Type (2017-2030)
• 6.5. Market Revenue, by Therapeutic Area (2017-2030)
• 6.6. Market Revenue, by End User (2017-2030)
• 6.7. Market Revenue, by Region (2017-2030)

Chapter 7. North America Market

• 7.1. Overview
• 7.2. Market Revenue, by Process (2017-2030)
• 7.3. Market Revenue, by Type (2017-2030)
• 7.4. Market Revenue, by Drug Type (2017-2030)
• 7.5. Market Revenue, by Therapeutic Area (2017-2030)
• 7.6. Market Revenue, by End User (2017-2030)
• 7.7. Market Revenue, by Country (2017-2030)

Chapter 8. Europe Market

• 8.1. Overview
• 8.2. Market Revenue, by Process (2017-2030)
• 8.3. Market Revenue, by Type (2017-2030)
• 8.4. Market Revenue, by Drug Type (2017-2030)
• 8.5. Market Revenue, by Therapeutic Area (2017-2030)
• 8.6. Market Revenue, by End User (2017-2030)
• 8.7. Market Revenue, by Country (2017-2030)

Chapter 9. APAC Market

• 9.1. Overview
• 9.2. Market Revenue, by Process (2017-2030)
• 9.3. Market Revenue, by Type (2017-2030)
• 9.4. Market Revenue, by Drug Type (2017-2030)
• 9.5. Market Revenue, by Therapeutic Area (2017-2030)
• 9.6. Market Revenue, by End User (2017-2030)
• 9.7. Market Revenue, by Country (2017-2030)

Chapter 10. LATAM Market

• 10.1. Overview
• 10.2. Market Revenue, by Process (2017-2030)
• 10.3. Market Revenue, by Type (2017-2030)
• 10.4. Market Revenue, by Drug Type (2017-2030)
• 10.5. Market Revenue, by Therapeutic Area (2017-2030)
• 10.6. Market Revenue, by End User (2017-2030)
• 10.7. Market Revenue, by Country (2017-2030)

Chapter 11. MEA Market

• 11.1. Overview
• 11.2. Market Revenue, by Process (2017-2030)
• 11.3. Market Revenue, by Type (2017-2030)
• 11.4. Market Revenue, by Drug Type (2017-2030)
• 11.5. Market Revenue, by Therapeutic Area (2017-2030)
• 11.6. Market Revenue, by End User (2017-2030)
• 11.7. Market Revenue, by Country (2017-2030)

Chapter 12. U.S. Market

• 12.1. Overview
• 12.2. Market Revenue, by Process (2017-2030)
• 12.3. Market Revenue, by Type (2017-2030)
• 12.4. Market Revenue, by Drug Type (2017-2030)
• 12.5. Market Revenue, by Therapeutic Area (2017-2030)
• 12.6. Market Revenue, by End User (2017-2030)

Chapter 13. Canada Market

• 13.1. Overview
• 13.2. Market Revenue, by Process (2017-2030)
• 13.3. Market Revenue, by Type (2017-2030)
• 13.4. Market Revenue, by Drug Type (2017-2030)
• 13.5. Market Revenue, by Therapeutic Area (2017-2030)
• 13.6. Market Revenue, by End User (2017-2030)

Chapter 14. Germany Market

• 14.1. Overview
• 14.2. Market Revenue, by Process (2017-2030)
• 14.3. Market Revenue, by Type (2017-2030)
• 14.4. Market Revenue, by Drug Type (2017-2030)
• 14.5. Market Revenue, by Therapeutic Area (2017-2030)
• 14.6. Market Revenue, by End User (2017-2030)

Chapter 15. France Market

• 15.1. Overview
• 15.2. Market Revenue, by Process (2017-2030)
• 15.3. Market Revenue, by Type (2017-2030)
• 15.4. Market Revenue, by Drug Type (2017-2030)
• 15.5. Market Revenue, by Therapeutic Area (2017-2030)
• 15.6. Market Revenue, by End User (2017-2030)

Chapter 16. U.K. Market

• 16.1. Overview
• 16.2. Market Revenue, by Process (2017-2030)
• 16.3. Market Revenue, by Type (2017-2030)
• 16.4. Market Revenue, by Drug Type (2017-2030)
• 16.5. Market Revenue, by Therapeutic Area (2017-2030)
• 16.6. Market Revenue, by End User (2017-2030)

Chapter 17. Italy Market

• 17.1. Overview
• 17.2. Market Revenue, by Process (2017-2030)
• 17.3. Market Revenue, by Type (2017-2030)
• 17.4. Market Revenue, by Drug Type (2017-2030)
• 17.5. Market Revenue, by Therapeutic Area (2017-2030)
• 17.6. Market Revenue, by End User (2017-2030)

Chapter 18. Spain Market

• 18.1. Overview
• 18.2. Market Revenue, by Process (2017-2030)
• 18.3. Market Revenue, by Type (2017-2030)
• 18.4. Market Revenue, by Drug Type (2017-2030)
• 18.5. Market Revenue, by Therapeutic Area (2017-2030)
• 18.6. Market Revenue, by End User (2017-2030)

Chapter 19. Japan Market

• 19.1. Overview
• 19.2. Market Revenue, by Process (2017-2030)
• 19.3. Market Revenue, by Type (2017-2030)
• 19.4. Market Revenue, by Drug Type (2017-2030)
• 19.5. Market Revenue, by Therapeutic Area (2017-2030)
• 19.6. Market Revenue, by End User (2017-2030)

Chapter 20. China Market

• 20.1. Overview
• 20.2. Market Revenue, by Process (2017-2030)
• 20.3. Market Revenue, by Type (2017-2030)
• 20.4. Market Revenue, by Drug Type (2017-2030)
• 20.5. Market Revenue, by Therapeutic Area (2017-2030)
• 20.6. Market Revenue, by End User (2017-2030)

Chapter 21. India Market

• 21.1. Overview
• 21.2. Market Revenue, by Process (2017-2030)
• 21.3. Market Revenue, by Type (2017-2030)
• 21.4. Market Revenue, by Drug Type (2017-2030)
• 21.5. Market Revenue, by Therapeutic Area (2017-2030)
• 21.6. Market Revenue, by End User (2017-2030)

Chapter 22. Australia Market

• 22.1. Overview
• 22.2. Market Revenue, by Process (2017-2030)
• 22.3. Market Revenue, by Type (2017-2030)
• 22.4. Market Revenue, by Drug Type (2017-2030)
• 22.5. Market Revenue, by Therapeutic Area (2017-2030)
• 22.6. Market Revenue, by End User (2017-2030)

Chapter 23. South Korea Market

• 23.1. Overview
• 23.2. Market Revenue, by Process (2017-2030)
• 23.3. Market Revenue, by Type (2017-2030)
• 23.4. Market Revenue, by Drug Type (2017-2030)
• 23.5. Market Revenue, by Therapeutic Area (2017-2030)
• 23.6. Market Revenue, by End User (2017-2030)

Chapter 24. Brazil Market

• 24.1. Overview
• 24.2. Market Revenue, by Process (2017-2030)
• 24.3. Market Revenue, by Type (2017-2030)
• 24.4. Market Revenue, by Drug Type (2017-2030)
• 24.5. Market Revenue, by Therapeutic Area (2017-2030)
• 24.6. Market Revenue, by End User (2017-2030)

Chapter 25. Mexico Market

• 25.1. Overview
• 25.2. Market Revenue, by Process (2017-2030)
• 25.3. Market Revenue, by Type (2017-2030)
• 25.4. Market Revenue, by Drug Type (2017-2030)
• 25.5. Market Revenue, by Therapeutic Area (2017-2030)
• 25.6. Market Revenue, by End User (2017-2030)

Chapter 26. Saudi Arabia Market

• 26.1. Overview
• 26.2. Market Revenue, by Process (2017-2030)
• 26.3. Market Revenue, by Type (2017-2030)
• 26.4. Market Revenue, by Drug Type (2017-2030)
• 26.5. Market Revenue, by Therapeutic Area (2017-2030)
• 26.6. Market Revenue, by End User (2017-2030)

Chapter 27. South Africa Market

• 27.1. Overview
• 27.2. Market Revenue, by Process (2017-2030)
• 27.3. Market Revenue, by Type (2017-2030)
• 27.4. Market Revenue, by Drug Type (2017-2030)
• 27.5. Market Revenue, by Therapeutic Area (2017-2030)
• 27.6. Market Revenue, by End User (2017-2030)

Chapter 28. U.A.E. Market

• 28.1. Overview
• 28.2. Market Revenue, by Process (2017-2030)
• 28.3. Market Revenue, by Type (2017-2030)
• 28.4. Market Revenue, by Drug Type (2017-2030)
• 28.5. Market Revenue, by Therapeutic Area (2017-2030)
• 28.6. Market Revenue, by End User (2017-2030)

Chapter 29. Competitive Landscape

• 29.1. List of Market Players and their Offerings
• 29.2. Competitive Benchmarking of Key Players
• 29.3. Product Benchmarking of Key Players
• 29.4. Recent Strategic Developments

Chapter 30. Company Profiles

• 30.1. Charles River Laboratories International Inc.
  • 30.1.1. Business overview
  • 30.1.2. Product and service offerings
  • 30.1.3. Key financial summary
• 30.2. Eurofins Scientific Limited
  • 30.2.1. Business overview
  • 30.2.2. Product and service offerings
  • 30.2.3. Key financial summary
• 30.3. Frontage Laboratories Inc.
  • 30.3.1. Business overview
  • 30.3.2. Product and service offerings
  • 30.3.3. Key financial summary
• 30.4. Galapagos NV
  • 30.4.1. Business overview
  • 30.4.2. Product and service offerings
  • 30.4.3. Key financial summary
• 30.5. General Electric
  • 30.5.1. Business overview
  • 30.5.2. Product and service offerings
  • 30.5.3. Key financial summary
• 30.6. Laboratory Corporation of America Holdings
  • 30.6.1. Business overview
  • 30.6.2. Product and service offerings
  • 30.6.3. Key financial summary
• 30.7. Thermo Fisher Scientific Inc.
  • 30.7.1. Business overview
  • 30.7.2. Product and service offerings
  • 30.7.3. Key financial summary
• 30.8. Syngene International Limited
  • 30.8.1. Business overview
  • 30.8.2. Product and service offerings
  • 30.8.3. Key financial summary
• 30.9. WuXi AppTec
  • 30.9.1. Business overview
  • 30.9.2. Product and service offerings
  • 30.9.3. Key financial summary

Chapter 31. Appendix

• 31.1. Abbreviations
• 31.2. Sources and References
• 31.3. Related Reports